OBVIOHEALTH, a Singapore and Orlando-based company offering mobile and “site-less” clinical trials, said on Friday it has raised US$3 million in Series A funding.
The financing round, led by TKS I, a life science and healthcare focused venture fund, will allow ObvioHealth to grow its operational team and support its current growth needs.
The company is focused on making clinical trials faster and more cost effective by digitising the entire process, while complying with FDA (Food and Drug Administration) Good Clinical Practices, it said.
ClaimIt, the company’s proprietary software, supports observational and interventional studies, allowing integration with smartphones, connected devices, and real-time interactions with subjects.
